Humana Price Target Cut by Analysts at Robert W. Baird

Analysts lowered the price target on the insurance provider's stock to $205.00 from $264.00.

Apr. 15, 2026 at 1:37pm

Got story updates? Submit your updates here. ›

A high-contrast, cinematic close-up of heavy, industrial banking machinery and financial infrastructure, conveying the tangible, physical nature of the financial systems impacting Humana's performance.An extreme close-up of the complex gears and mechanisms that power the financial industry, a visual metaphor for the institutional forces shaping Humana's outlook.Louisville Today

Analysts at Robert W. Baird have reduced their price target on shares of Humana (NYSE:HUM) from $264.00 to $205.00. The brokerage firm maintained a 'neutral' rating on the insurance provider's stock.

Why it matters

This price target cut reflects analysts' concerns about Humana's near-term outlook and valuation. As a major player in the health insurance industry, Humana's performance is closely watched by investors and can signal broader trends in the sector.

The details

In a research report, Robert W. Baird analysts cited a number of factors that led to the reduced price target, including the competitive landscape and regulatory environment facing Humana. The new $205.00 price target suggests a potential upside of 4.55% from the company's current trading price.

  • The new price target was issued on April 15, 2026.

The players

Humana

A major health insurance company headquartered in Louisville, Kentucky that primarily serves individuals and groups across the United States, with a focus on Medicare Advantage plans and prescription drug coverage.

Robert W. Baird

An investment banking and asset management firm that provides research coverage on Humana's stock.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Humana's upcoming earnings report and any further updates from analysts on the company's outlook.

The takeaway

This price target reduction reflects broader concerns about the health insurance industry's competitive and regulatory environment, which could impact Humana's near-term performance and valuation.